MRI-Based Quantification of Intratumoral Heterogeneity Predicts Response in Hepatocellular Carcinoma Treated with Atezolizumab-Bevacizumab and TACE/HAIC
Academic Radiology · 2025-11 · 32 (11) · 6451-6462
DOI: 10.1016/j.acra.2025.06.025 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Academic Radiology, 2025-11. Verfasst von Hai-Tao Yan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China (H.T.Y., Q.Q.Z., S.L., H…. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Bevacizumab, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Nanjing Medical University.
Abstract (Originalsprache)
RATIONALE AND OBJECTIVES: Hepatocellular carcinoma (HCC) is highly heterogeneous, resulting in different treatment responses to anti-tumor therapy. The present study aimed to investigate the prognostic value of noninvasive MRI-based intratumoral heterogeneity (ITH) quantification for predicting treatment response to atezolizumab-bevacizumab combined with transarterial chemoembolization (TACE) /hepatic artery infusion chemotherapy (HAIC) in unresectable HCC. MATERIALS AND METHODS: Patients with unresectable HCC (n=151) who received atezolizumab-bevacizumab combined with TACE/HAIC at multiple centers were enrolled between January 2019 and January 2024. Conventional and habitat radiomic features were extracted from MRI to construct the ITH score. Predictive models based on clinical variables, radiomic features, and the ITH score were developed and evaluated using the area under the receiver operating characteristic curve (AUC). RESULTS: 88 patients (58.3%) showed a response to atezolizumab-bevacizumab combined with TACE/HAIC. The combined model integrating clinical variables, radiomic features, and the ITH score achieved the highest accuracy in predicting treatment response to triple therapy with an AUC of 0.971, 0.937, and 0.868 in the training, validation, and testing cohort, respectively. Furthermore, the combined model can categorize patients into high-risk and low-risk groups for progression-free survival (PFS) and overall survival (OS) in the training (p < 0.001 for PFS and OS), validation (p < 0.001 for PFS and OS) and testing cohort (p = 0.005 for PFS; p < 0.001 for OS). CONCLUSION: The MRI-based ITH score, when combined with clinical and radiomic features, provides a robust predictive tool for treatment response in HCC patients undergoing atezolizumab-bevacizumab combined with TACE/HAIC. DATA AVAILABILITY STATEMENT: The datasets generated or analyzed during the study are available from the corresponding author on reasonable request.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Interventional Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China (H.T.Y., Q.Q.Z., S.L., H.B.S., J.X.Z.).
- Department of Pathology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China (H.J.H.).
- Department of Radiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310020, China (W.L.F.).
- Department of Medical Oncology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, China (Y.C.).
- Department of Computer Science and Technology, Zhejiang University, Hangzhou 310000, China (Z.L.F.).
- Department of Interventional Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China (H.T.Y., Q.Q.Z., S.L., H.B.S., J.X.Z.). Electronic address: zhangjinxing@njmu.edu.cn.
Förderung
- Nanjing Medical University
Zitieren
APA
Yan, H. T., Zu, Q. Q., Hua, H. J., Fan, W. L., Cheng, Y., Liu, S., Shi, H. B., Feng, Z. L., & Zhang, J. X. (2025). MRI-Based Quantification of Intratumoral Heterogeneity Predicts Response in Hepatocellular Carcinoma Treated with Atezolizumab-Bevacizumab and TACE/HAIC. Academic Radiology, 32(11), 6451-6462. https://doi.org/10.1016/j.acra.2025.06.025
Vancouver
Yan HT, Zu QQ, Hua HJ, Fan WL, Cheng Y, Liu S, et al. MRI-Based Quantification of Intratumoral Heterogeneity Predicts Response in Hepatocellular Carcinoma Treated with Atezolizumab-Bevacizumab and TACE/HAIC. Academic Radiology. 2025;32(11):6451-6462. doi:10.1016/j.acra.2025.06.025
BibTeX
@article{Yan2025,
author = {Yan, Hai-Tao and Zu, Qing-Quan and Hua, Hong-Jin and Fan, Wen-Long and Cheng, Yuan and Liu, Sheng and Shi, Hai-Bin and Feng, Zun-Lei and Zhang, Jin-Xing},
title = {MRI-Based Quantification of Intratumoral Heterogeneity Predicts Response in Hepatocellular Carcinoma Treated with Atezolizumab-Bevacizumab and TACE/HAIC},
journal = {Academic Radiology},
year = {2025},
volume = {32},
number = {11},
pages = {6451--6462},
doi = {10.1016/j.acra.2025.06.025}
}
EUVIMED